Umer Raffat

Selected news for Umer Raffat, representing 5% of data collected since 2/2018. Recent stories appear in BioSpace and MSN. This person shares healthcare news with Gilead, Biogen, Gilead Sciences, Biogen Inc. and dozens of others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
12/4/2020 Investors send Bristol Myers' CVR soaring on rekindled hopes for timely CAR-T site inspection FiercePharma ... company’s CEO, Scott Koenig, said at Evercore ISI’s annual HealthCONx event Wednesday.The site belongs to contract manufacturer AGC Biologics in Seattle, and the inspection was conducted in person, Evercore ISI analyst Umer Raffat wrote in an investor note Thursday. The CDMO didn’t immediately respond to a Fierce Pharma request for confirmation.By itself, the drug isn’t the most important candidate in Macrogenics’ portfolio, according ...
11/25/2020 Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference ask.com ... antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM EST.Dr. Buell will provide an update on clinical programs, including AGEN1181, and corporate progress ...
11/23/2020 RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences BioSpace ... it will present and participate at the following virtual conferences in December:Evercore ISI 3 rd Annual HealthCONx Conference Fireside chat and an open Q&A: Thursday, December 3, 2020 , 8 a.m. EST Moderator: Umer Raffat , Equity Research – Biotech-large, Pharma-major, Specialty Pharma Speaker: Dror Ben-Asher , CEO & Gilead Raday , Chief Operating OfficerPiper Sandler 32 nd Annual Virtual Healthcare Conference Fireside chat: Available on-demand from November ...
11/17/2020 FDA unexpectedly rejects Alkermes schizophrenia drug, citing manufacturing concerns biopharmadive.com ... because of the coronavirus epidemic.Any "slight issues" in manufacturing might generate a rejection instead of an approval, with the FDA failing to ask for clarification during a remote review process, Evercore ISI analyst Umer Raffat wrote in a note to investors.In the case of Alkermes, regulators conducted a remote review of records, confirmed receipt of information they requested from the company on Sept. 11 and then didn't provide ...
11/10/2020 Amgen's asthma drug delivers a needed win biopharmadive.com ... Amgen's tezepelumab showed significant reductions in asthma exacerbations — sometimes called asthma attacks — compared to those who got a placebo. More detailed data will be presented at an upcoming medical meeting, Amgen said. Umer Raffat , an analyst at Evercore ISI, called the results a "best-case outcome" for Amgen and tezepelumab, especially considering the drug had failed as an eczema treatment a few years back. "I expect Amgen to ...
11/3/2020 Bausch Health Companies Inc. (BHC) Q3 2020 Earnings Call Transcript alphastreet.com ... in order to continue to build what we hope will be a best-in-class product for the contact lens wearers through the SiHy Daily.Operator, next question, please.Our next question comes from Umer Raffat with Evercore. Please go ahead.Umer Raffat — Evercore ISI — AnalystHi. Thanks so much for taking my questions. I think perhaps the first one is the obvious one from the Print, which ...
10/29/2020 Amgen Inc. (AMGN) Q3 2020 Earnings Call Transcript alphastreet.com ... that we will be discussing next steps.Arvind Sood — Vice President of Investor RelationsOkay, April. Let’s take the next question please.OperatorAnd your next question comes from the line of Umer Raffat from Evercore ISI.Umer Raffat — Evercore ISI — AnalystHi, thanks so much for taking my question. I had two here, if I may. First, I know there’s a lot of focus ...
10/21/2020 Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research universdev.com ... founder and Chairman, was awarded the 1 position in Economics, a recognition he has earned 40 times. David Raso, who covers Machinery, Engineering and Construction, was ranked 1 for the 20th time. In addition, Umer Raffat , Evercore ISI’s Pharmaceuticals and Large-Cap Biotech analyst, was named to II’s Hall of Fame having received ten 1 positions over the years. In all, Evercore ISI claimed a Firm record 39 individual positions ...
10/21/2020 Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research gurufocus.com ... and Chairman, was awarded the 1 position in Economics, a recognition he has earned 40 times. David Raso, who covers Machinery, Engineering and Construction, was ranked 1 for the 20 th time. In addition, Umer Raffat , Evercore ISI’s Pharmaceuticals and Large-Cap Biotech analyst, was named to II’s Hall of Fame having received ten 1 positions over the years. In all, Evercore ISI claimed a Firm record 39 individual positions ...
10/21/2020 Biogen Inc. (BIIB) Q3 2020 Earnings Call Transcript alphastreet.com ... In terms of your question on inventory, I would just say it wasn’t a significant impact in the quarter and not something that we called out.OperatorWe will take our next question from Umer Raffat with Evercore ISI.Umer Raffat — Evercore ISI — AnalystHi, guys. Thanks for taking my question. Michel, I know you were super excited the day you guys decided to file with FDA. I don’t know ...
10/20/2020 The The Crisis Responders institutionalinvestor.com ... at the center of the economic and public health crises. Some, like Glass and Keay, had the impossible task of predicting the future of companies that had been completely disrupted. Others, like pharmaceuticals analyst Umer Raffat and telecom researcher Tal Liani, watched investor demand surge for their stocks, which were seen as part of the solution to 2020’s biggest challenges.Below, five crisis stars share their views on some ...
10/10/2020 Pfizer trying to defuse critics amid push for vaccine before Election Day areyoupop.com ... to a late October announcement that it’s found a working vaccine. “The moment that data is processed and reported to management, they basically have to put out a press release, irrespective of politics,” said Umer Raffat , an analyst at investment bank Evercore ISI. Pfizer spokesperson Sharon Castillo downplayed the company’s efforts to head off criticism, calling its meetings with scientists a standard practice. “This is not something out of the ...
10/6/2020 Amgen teases 'promising' phase 2 data for closely watched KRAS prospect FierceBiotech ... Despite the paucity of information on the phase 2 results, industry watchers are optimistic. Jefferies analyst Michael Yee expects an FDA filing soon, he wrote in a note to clients, while Evercore ISI analyst Umer Raffat extrapolated his way to some conclusions and deemed the data “v good.” Based on when the trial finished enrolling—January of this year—and when submissions closed for WCLC, Raffat inferred the data cutoff ...
9/21/2020 ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer FiercePharma ... received drug treatment before surgery, focusing on those with high-risk markers. Nevertheless, the monarchE success now puts Verzenio on track to become the first to enter the adjuvant setting, which Evercore ISI analyst Umer Raffat previously predicted could be a $3 billion to $4 billion indication. An approval based on the monarchE trial could increase Verzenio’s addressable population by at least 50%, said Jack Goodpasture, senior director of medical ...
9/19/2020 ESMO: Pfizer's Ibrance flop in early breast cancer shouldn't hurt metastatic sales, exec says FiercePharma ... breast cancer, they look at early breast cancer very differently from metastatic,” he said, adding that “we do not expect any impact on Ibrance’s … positioning or performance in the metastatic setting.” Evercore ISI analyst Umer Raffat , for his part, agreed. "Could this increase % share in metastatic? I doubt it," Raffat wrote in a note to clients following Lilly’s top-line release in June ...